Disease progression patterns of bevacizumab responders with recurrent malignant gliomas

Tumor progression in patients with recurrent malignant glioma who respond to bevacizumab (BEV) is difficult to assess. The current study reviewed the clinical and radiological results of patients following a BEV-based chemotherapy regimen, and evaluated disease progression patterns in patients who r...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncol Lett
Main Authors: Kim, Ju-Hwi, Jung, Tae-Young, Hwang, Eu Chang, Jung, Sung-Hoon, Jung, Shin, Kim, In-Young, Jang, Woo-Youl, Moon, Kyung-Sub, Lee, Kyung-Hwa, Kim, Seul-Kee
Format: Artigo
Jezik:Inglês
Izdano: D.A. Spandidos 2017
Teme:
Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5588053/
https://ncbi.nlm.nih.gov/pubmed/28927109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6630
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki